177 related articles for article (PubMed ID: 27525648)
1. Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice.
Sato H; Kubota N; Kubota T; Takamoto I; Iwayama K; Tokuyama K; Moroi M; Sugi K; Nakaya K; Goto M; Jomori T; Kadowaki T
Diabetologia; 2016 Nov; 59(11):2426-2434. PubMed ID: 27525648
[TBL] [Abstract][Full Text] [Related]
2. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle.
Kubota T; Kubota N; Kumagai H; Yamaguchi S; Kozono H; Takahashi T; Inoue M; Itoh S; Takamoto I; Sasako T; Kumagai K; Kawai T; Hashimoto S; Kobayashi T; Sato M; Tokuyama K; Nishimura S; Tsunoda M; Ide T; Murakami K; Yamazaki T; Ezaki O; Kawamura K; Masuda H; Moroi M; Sugi K; Oike Y; Shimokawa H; Yanagihara N; Tsutsui M; Terauchi Y; Tobe K; Nagai R; Kamata K; Inoue K; Kodama T; Ueki K; Kadowaki T
Cell Metab; 2011 Mar; 13(3):294-307. PubMed ID: 21356519
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.
Nakaya K; Kubota N; Takamoto I; Kubota T; Katsuyama H; Sato H; Tokuyama K; Hashimoto S; Goto M; Jomori T; Ueki K; Kadowaki T
Metabolism; 2013 Jul; 62(7):939-51. PubMed ID: 23790528
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.
Ikedo T; Minami M; Kataoka H; Hayashi K; Nagata M; Fujikawa R; Higuchi S; Yasui M; Aoki T; Fukuda M; Yokode M; Miyamoto S
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28630262
[TBL] [Abstract][Full Text] [Related]
5. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism.
Ishii M; Shibata R; Kondo K; Kambara T; Shimizu Y; Tanigawa T; Bando YK; Nishimura M; Ouchi N; Murohara T
J Biol Chem; 2014 Sep; 289(39):27235-27245. PubMed ID: 25100725
[TBL] [Abstract][Full Text] [Related]
6. Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway.
Vellecco V; Mitidieri E; Gargiulo A; Brancaleone V; Matassa D; Klein T; Esposito F; Cirino G; Bucci M
Diabetes Obes Metab; 2016 Dec; 18(12):1236-1243. PubMed ID: 27460695
[TBL] [Abstract][Full Text] [Related]
7. Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice.
Yamashita S; Kawakami Y; Sato H; Sugitani S; Goto M; Kato N
Eur J Pharmacol; 2019 Sep; 859():172521. PubMed ID: 31276666
[TBL] [Abstract][Full Text] [Related]
8. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
[TBL] [Abstract][Full Text] [Related]
9. The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation.
Furuta S; Goto M; Tamura M; Yamashita S; Nakaya K; Furuta Y
Drug Res (Stuttg); 2014 Mar; 64(3):130-5. PubMed ID: 23965798
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
Takada S; Masaki Y; Kinugawa S; Matsumoto J; Furihata T; Mizushima W; Kadoguchi T; Fukushima A; Homma T; Takahashi M; Harashima S; Matsushima S; Yokota T; Tanaka S; Okita K; Tsutsui H
Cardiovasc Res; 2016 Sep; 111(4):338-47. PubMed ID: 27450980
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis.
Mimura S; Ando T; Ishiguro K; Maeda O; Watanabe O; Ujihara M; Hirayama Y; Morise K; Maeda K; Matsushita M; Funasaka K; Nakamura M; Miyahara R; Ozaki N; Goto H
Scand J Gastroenterol; 2013 Oct; 48(10):1152-9. PubMed ID: 24047394
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment.
Dong Z; Chai W; Wang W; Zhao L; Fu Z; Cao W; Liu Z
Am J Physiol Endocrinol Metab; 2013 Jan; 304(2):E222-8. PubMed ID: 23193054
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance.
Sjøberg KA; Rattigan S; Jeppesen JF; Lundsgaard AM; Holst JJ; Kiens B
J Physiol; 2015 May; 593(9):2185-98. PubMed ID: 25688993
[TBL] [Abstract][Full Text] [Related]
14. The role of endothelial insulin signaling in the regulation of glucose metabolism.
Kubota T; Kubota N; Kadowaki T
Rev Endocr Metab Disord; 2013 Jun; 14(2):207-16. PubMed ID: 23589150
[TBL] [Abstract][Full Text] [Related]
15. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism.
Chai W; Dong Z; Wang N; Wang W; Tao L; Cao W; Liu Z
Diabetes; 2012 Apr; 61(4):888-96. PubMed ID: 22357961
[TBL] [Abstract][Full Text] [Related]
17. DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.
Shinjo T; Nakatsu Y; Iwashita M; Sano T; Sakoda H; Ishihara H; Kushiyama A; Fujishiro M; Fukushima T; Tsuchiya Y; Kamata H; Nishimura F; Asano T
Am J Physiol Endocrinol Metab; 2015 Aug; 309(3):E214-23. PubMed ID: 26015438
[TBL] [Abstract][Full Text] [Related]
18. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
19. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.
Ervinna N; Mita T; Yasunari E; Azuma K; Tanaka R; Fujimura S; Sukmawati D; Nomiyama T; Kanazawa A; Kawamori R; Fujitani Y; Watada H
Endocrinology; 2013 Mar; 154(3):1260-70. PubMed ID: 23337530
[TBL] [Abstract][Full Text] [Related]
20. Endothelial Fcγ Receptor IIB Activation Blunts Insulin Delivery to Skeletal Muscle to Cause Insulin Resistance in Mice.
Tanigaki K; Chambliss KL; Yuhanna IS; Sacharidou A; Ahmed M; Atochin DN; Huang PL; Shaul PW; Mineo C
Diabetes; 2016 Jul; 65(7):1996-2005. PubMed ID: 27207525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
